- Home
- SHOT vs ITRM Comparison
SHOT vs ITRM Comparison
Compare SHOT & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHOT
- ITRM
- Stock Information
- Founded
- SHOT 2018
- ITRM 2015
- Country
- SHOT United States
- ITRM Ireland
- Employees
- SHOT N/A
- ITRM N/A
- Industry
- SHOT Biotechnology: Pharmaceutical Preparations
- ITRM Biotechnology: Pharmaceutical Preparations
- Sector
- SHOT Health Care
- ITRM Health Care
- Exchange
- SHOT Nasdaq
- ITRM Nasdaq
- Market Cap
- SHOT 30.4M
- ITRM 36.3M
- IPO Year
- SHOT 2020
- ITRM 2018
- Fundamental
- Price
- SHOT $0.29
- ITRM $1.00
- Analyst Decision
- SHOT
- ITRM Strong Buy
- Analyst Count
- SHOT 0
- ITRM 2
- Target Price
- SHOT N/A
- ITRM $7.00
- AVG Volume (30 Days)
- SHOT 2.0M
- ITRM 628.6K
- Earning Date
- SHOT 05-15-2025
- ITRM 05-13-2025
- Dividend Yield
- SHOT N/A
- ITRM N/A
- EPS Growth
- SHOT N/A
- ITRM N/A
- EPS
- SHOT N/A
- ITRM N/A
- Revenue
- SHOT $573,336.00
- ITRM N/A
- Revenue This Year
- SHOT N/A
- ITRM N/A
- Revenue Next Year
- SHOT N/A
- ITRM $108.39
- P/E Ratio
- SHOT N/A
- ITRM N/A
- Revenue Growth
- SHOT 69.32
- ITRM N/A
- 52 Week Low
- SHOT $0.26
- ITRM $0.81
- 52 Week High
- SHOT $1.77
- ITRM $3.02
- Technical
- Relative Strength Index (RSI)
- SHOT 27.09
- ITRM 47.60
- Support Level
- SHOT $0.26
- ITRM $0.89
- Resistance Level
- SHOT $0.45
- ITRM $1.00
- Average True Range (ATR)
- SHOT 0.05
- ITRM 0.05
- MACD
- SHOT -0.02
- ITRM 0.01
- Stochastic Oscillator
- SHOT 10.38
- ITRM 68.75
About SHOT Safety Shot Inc.
Safety Shot Inc is a wellness and functional beverage company. It is set to launch Safety Shot, the patented beverage that helps people feel faster by reducing blood alcohol content and boosting clarity.
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.